Apelin/APJ system: A key therapeutic target for liver disease
Metrics: PDF 672 views | HTML 1452 views | ?
Shuang-Yu Lv1, Binbin Cui1, Wei-Dong Chen1,3 and Yan-Dong Wang2
1Key Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Medicine, Henan University, Kaifeng, Henan, P. R. China
2State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China
3Key Laboratory of Molecular Pathology, School of Basic Medical Science, Inner Mongolia Medical University, Hohhot, Inner Mongolia, P. R. China
Yan-Dong Wang, email: firstname.lastname@example.org
Wei-Dong Chen, email: email@example.com
Keywords: apelin; APJ; liver; cirrhosis; fibrosis
Received: April 19, 2017 Accepted: November 11, 2017 Published: December 01, 2017
Apelin, a new bioactive peptide, was identified as an endogenous ligand for APJ (Angiotensin II receptor-like 1). Apelin and its receptor have an abundant distribution in central nervous system and peripheral tissues, including liver. Apelin/APJ has diverse physiological and pathological effects, including regulation of cardiovascular function, angiogenesis, fluid homeostasis and so on. Apelin/APJ system may act as a novel potential therapeutic target for liver disease. In this article, we review the role of apelin/APJ system in liver fibrosis, hepatitis, hepatic cirrhosis, liver injury and metabolic liver disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.